Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anwaar Saeed

Showing results (131-140 of 167) with videos related to

Pageof 17
Sort By:
Therapeutic Advances in Medical Oncology|May 17, 2021
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinomaTomi Jun, Umut Ozbek, Sirish Dharmapuri, et al.
Cancers|July 16, 2020
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI GradeDavid J Pinato, Takahiro Kaneko, Anwaar Saeed, et al.
Frontiers in Oncology|March 3, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitorsY Linda Wu, Grace van Hyfte, Umut Özbek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced MalignanciesBenedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Journal for Immunotherapy of Cancer|September 2, 2020
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international studyPetros Fessas, Ahmed Kaseb, Yinghong Wang, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapyDavid J Pinato, Ahmed Kaseb, Yinghong Wang, et al.
Nature Medicine|March 30, 2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trialZev A Wainberg, Gulam A Manji, Nathan Bahary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO GuidelineManish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, et al.
Hepatology Communications|April 28, 2022
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCCRohini Sharma, Anjana Pillai, Thomas Urban Marron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global ExperienceSteven B Maron, Stephanie Moya, Federica Morano, et al.
Pageof 17

Showing results (131-140 of 167) with videos related to

Sort By:
Pageof 17
Therapeutic Advances in Medical Oncology|May 17, 2021
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinomaTomi Jun, Umut Ozbek, Sirish Dharmapuri, et al.
Cancers|July 16, 2020
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI GradeDavid J Pinato, Takahiro Kaneko, Anwaar Saeed, et al.
Frontiers in Oncology|March 3, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitorsY Linda Wu, Grace van Hyfte, Umut Özbek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced MalignanciesBenedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Journal for Immunotherapy of Cancer|September 2, 2020
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international studyPetros Fessas, Ahmed Kaseb, Yinghong Wang, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapyDavid J Pinato, Ahmed Kaseb, Yinghong Wang, et al.
Nature Medicine|March 30, 2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trialZev A Wainberg, Gulam A Manji, Nathan Bahary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO GuidelineManish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, et al.
Hepatology Communications|April 28, 2022
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCCRohini Sharma, Anjana Pillai, Thomas Urban Marron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global ExperienceSteven B Maron, Stephanie Moya, Federica Morano, et al.
Pageof 17